AI Article Synopsis
- * Out of these patients, 81% successfully underwent bilateral prostatic artery embolization, showing significant improvement in International Prostate Symptom Score, quality of life, and erectile function after an average follow-up of 42 days.
- * The treatment resulted in an average prostate volume reduction of 28 mL (16.2%), with only one minor adverse event (hematospermia) reported from two cases of nontarget embolization.
Article Abstract
This retrospective report describes treatment of 21 patients who underwent prostatic artery embolization using 70- to 150-μm radiopaque microspheres for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Seventeen patients (81%) received successful bilateral prostatic artery embolization. At a mean follow-up of 42 days (range, 25-59 days), patients showed improvement in International Prostate Symptom Score (n = 11; mean = 10.6; P = .001), quality of life score (n = 17; mean = 2.0; P = .02), and International Index of Erectile Function (n = 17; mean = 9.3; P = .01). The mean prostate volume reduction was 28 mL (16.2%; P = .003). Nontarget embolization occurred twice, resulting in 1 minor adverse event of hematospermia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jvir.2020.02.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prostatic Artery Embolization in Elderly Comorbid Patients with Benign Prostatic Hyperplasia: Safety, Efficacy, and Predictive Factors of Clinical Failure.
J Pers Med
January 2025
Urology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, 34126 Trieste, Italy.
: This study aims to evaluate the safety and efficacy of prostatic artery embolization (PAE) in elderly, multimorbid patients with benign prostatic hyperplasia (BPH). Additionally, it seeks to identify technical and clinical factors that predict clinical failure at the mid-term follow-up. : We analyzed the clinical records of 175 consecutive patients who underwent PAE.
View Article and Find Full Text PDFAngiographic Analysis of Anatomical Variants in 242 Hemorrhoidal Artery Embolization.
J Vasc Interv Radiol
January 2025
Prostate Centers USA, 1801 Robert Fulton Drive Suite 510, Reston, VA 20191.
Evaluating Graft Loss Risk in Living-Donor Kidney Transplants with Multiple Renal Arteries.
Ann Transplant
December 2024
Department of Urology, Nara Medical University, Kashihara, Nara, Japan.
BACKGROUND Despite its surgical complexity, kidney transplantation (KT) with multiple renal arteries (MRA) is comparable in performance to KT with a single renal artery (SRA). This study aimed to evaluate the effect of MRA and to investigate risk factors for graft loss in living-donor KT with MRA. MATERIAL AND METHODS This study included living-donor KT recipients who underwent KT in our hospital from February 2002 to March 2023.
View Article and Find Full Text PDFProstatic Artery Embolization for Refractory Hematospermia without Hematuria.
J Vasc Interv Radiol
January 2025
Department of Radiology.
Potential beneficial impacts of tadalafil on cardiovascular diseases.
J Chin Med Assoc
January 2025
Department and Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor commonly used for the treatment of erectile dysfunction and benign prostatic hyperplasia. Its mechanism of action involves the inhibition of PDE5, leading to increased levels of nitric oxide and cyclic guanosine monophosphate in the corpus cavernosum, which facilitates smooth muscle relaxation. This article reviews studies using tadalafil in the treatment of cardiovascular diseases and emphasizes its potential advantages in conditions such as pulmonary arterial hypertension, atherosclerosis, coronary artery disease, myocardial infarction, heart failure, stroke, diabetic ulcers, and cardiomyopathy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!